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Abstract
Purpose: For patients with hepatocellular carcinoma awaiting liver transplantation (LT), stereotactic body radiation therapy (SBRT) has
emerged as a bridging treatment to ensure patients maintain priority status and eligibility per Milan criteria. In this study, we aimed to
determine the efficacy and safety of SBRT in such situations.
Methods and Materials: A retrospective analysis was conducted of the outcomes of 27 patients treated with SBRT who were listed for
LT at 1 institution. Among these, 20 patients with 26 tumors went on to LT and were the focus of this study. Operative reports and
postoperative charts were evaluated for potential radiation-related complications. The explant pathology findings were correlated with
equivalent dose in 2 Gy fractions and tumor size.
Results: Median pretreatment tumor size was 3.05 cm. Median total dose of radiation was 50 Gy delivered in 5 fractions. Pathologic
complete response (pCR) was achieved in 16 tumors (62%). Median interval from end of SBRT to transplant was 287 days. Of the 21
tumors imaged before transplant, 16 or 76% demonstrated a clinical complete response based on modified Response Evaluation Criteria
in Solid Tumors criteria. There was no significant correlation between pCR rate and increasing tumor size (odds ratio [OR], 0.95; 95%
confidence interval, 0.595-1.53) or pCR rate and equivalent dose in 2 Gy fractions (OR, 1.03; 95% confidence interval, 0.984-1.07.) No
patients experienced radiation-related operative or postoperative complications. Of the 27 patients who were listed for transplant, the
dropout rate was 22%. Two of the 5 patients with Child-Pugh score 10 died of liver failure.
Conclusions: These data demonstrate that SBRT as a bridging modality is a feasible option, with a pCR rate comparable to that of other
bridging modalities and no additional radiation-related operative or postoperative complications. There was no dose dependence nor size
dependence for pCR rate, which may indicate that for the tumor sizes in this study, the radiation doses delivered were sufficiently high.
 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer death and fifth most common cancer
worldwide, with increased incidence in regions where
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there is prevalence of hepatitis B and C infection,
including eastern Asia, southeast Asia, and middle Af-
rica. The incidence in the United States has grown due
to a rising number of patients diagnosed with hepatitis
C. Management options include surgical resection; local
ablative techniques such as transarterial chemo-
embolization (TACE), radiofrequency ablation (RFA),
microwave ablation (MWA), or stereotactic body radi-
ation therapy (SBRT); systemic therapy; immuno-
therapy; and liver transplantation (LT). Of these, LT has
been associated with the best outcomes in those patients
who are deemed eligible.1
Patients who are listed for LT can face prolonged
wait times, during which local progression can result in
loss of priority status due to ineligibility per Milan
criteria, defined as a solitary HCC nodule 5 cm or up
to 3 HCC nodules each 3 cm without vascular in-
vasion or metastasis.2 Treatment modalities such as
TACE and RFA among others provide local treatment
during this time as a bridge to transplant, which can
prevent tumor progression and therefore reduce dropout.
In addition, due to recent policy changes, there are an
increasing number of patients on the wait list being
considered for bridging therapies. The updated Amer-
ican Association for the Study of Liver Disease
guidelines state that patients with an anticipated wait
time of greater than 6 months should be considered for
a local therapy depending on their level of hepatic
dysfunction.3 An updated policy in 2015 requires that
patients are listed for 6 months before receiving their
Model for End-Stage Liver Disease exception points,
which give increased priority to patients on the trans-
plant list with HCC whose Model for End-Stage Liver
Disease score may not accurately reflect the severity of
their disease.4 Thus, nearly all patients with HCC
awaiting LT should be considered for bridging
treatments.
Historically, radiation therapy (RT) has been used
sparingly in the treatment of HCC, as efficacy is
limited by concerns for toxicity, particularly radiation-
induced liver disease.1 However, liver treatment with
dose escalation and hypofractionation has become
possible with improved conformality due to advance-
ments in image guidance and tumor motion manage-
ment. Thus, SBRT has emerged as a local treatment
modality that can be used for bridging as an alterna-
tive to the aforementioned possibilities.5 Patients are
often offered SBRT if they are ineligible for TACE or
RFA due to liver dysfunction, larger lesion size,
locational challenges of the tumor, or presence of
multiple lesions. Additionally, many patients are
treated with SBRT as salvage after failure of other
local treatments.6,7 In our study, we aimed to deter-
mine the efficacy and safety of patients treated with
SBRT as a bridging modality to transplant at our
institution.
Methods and Materials
With institutional review board approval, a retrospec-
tive analysis was conducted of the outcomes of 27 pa-
tients with HCC who were treated with SBRT as a bridge
to transplant between 2012 and 2018. Among these, 20
patients with 26 tumors went on to LT and were the focus
of this study. All cases were discussed in a multidisci-
plinary conference including diagnostic radiology, inter-
ventional radiology, transplant surgery, hepatology,
medical oncology, and radiation oncology. Patients were
not required to have pathologic confirmation of their
diagnosis if radiographic criteria were sufficient. Patients
were included regardless of whether they had prior local
liver-directed therapies, including TACE, transarterial
embolization, drug-eluting bead TACE, RFA, and MWA.
For radiation treatment, patients were positioned su-
pine on a vacuum cushion, which was custom molded,
and a treatment planning helical computed tomography
(CT) followed by a 4-dimensional CT were obtained to
account for respiratory motion. Images were fused with
patient’s diagnostic imaging including either 4 phase CT
or magnetic resonance imaging to assist in tumor delin-
eation. The target volume was then expanded accordingly
to account for respiratory motion. Patients were treated to
a total dose of 30 to 63 Gy in 3 to 6 fractions. Planning
was performed using volumetric modulated arc therapy.
Before each treatment, cone beam CT scans and kilo-
voltage orthogonal films were obtained and aligned with
the treatment planning CT.
All patients were followed after SBRT with CT or
magnetic resonance imaging of the abdomen and follow-
up in the HCC multidisciplinary clinic initially at 1 month
and then at 3 month intervals after treatment until LT.
Three patients had a shortened interval to transplant and
thus did not obtain postradiation treatment imaging. No
patients were lost to follow-up. Tumor response on im-
aging was evaluated based on modified Response Eval-
uation Criteria in Solid Tumors (mRECIST.) Operative
reports and postoperative charts were evaluated for
complications that could be related to radiation. The
explant pathology findings were correlated with equiva-
lent dose in 2 Gy fractions (EQD2) and tumor size. Sta-
tistical analysis was performed with IBM Statistical
Package for Social Sciences software using a binary
logistic regression technique.
Results
The median age of patients treated at our institution
was 62 (range, 41-71). The median pretreatment tumor
size of those who went on to transplant was 3.05 cm
(range, 0.7-10). The median total dose of radiation was 50
Gy (range, 30-63) delivered in 5 fractions, with a detailed
breakdown of the doses and fractionation in Table 1 in
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addition to relevant clinical characteristics of patients. A
summary of tumor and treatment details is shown in
Table 2. Median EQD2 delivered was 71.7 Gy (range,
40-126). There were 10 patients who were classified as
Child- Pugh (CP) score A at the time of radiation. Three
patients had a CP B score 7 and 5 had a CP B score 8 to
10. The remaining 2 patients were classified as
CP C score 10. Eighty-five percent of patients had 1
lesion treated. Three patients had 3 lesions treated with
SBRT, which were evaluated individually at the time of
LT. Eighty-five percent of patients had disease that
radiographically fell within Milan criteria. Of the
remaining 15%, or 3 patients, 1 was down staged to
within Milan and 2 patients who were clinically beyond
Milan at the time of transplant received extended criteria
donor livers. Twenty-two lesions had received prior
treatments with a combination of TACE, transarterial
embolization, drug-eluting bead TACE, RFA, and MWA.
Eleven lesions received SBRT as a part of a planned
combined modality approach and the remaining 11
received SBRT as salvage.
A summary of the radiographic and pathologic out-
comes after SBRT is shown in Table 3. There was path-
ologic complete response (pCR) achieved in 16 tumors
(62%). Median interval from end of SBRT to transplant
was 287 days (range, 9-2100). Two patients had a rela-
tively shortened interval to transplant of 9 and 18 days
and had a pathologic partial response. Restaging imaging
was performed after SBRT and before transplant in 21
tumors. Sixteen, or 76%, demonstrated a clinical complete
response based on mRECIST criteria. Of the 27 patients
who were listed for transplant, the dropout rate was 22%,
or 6 patients. Among these, 4 patients passed away. Two
passed away from liver failure, 1 from an unknown cause,
and 1 due to congestive heart failure exacerbation. Both
patients who died due to liver failure were patients with a
CP score of C10. The first patient with CP score C10 who
died of liver failure had a tumor volume of 115.2 cm3 and
mean liver dose of 5.6 Gy. Radiation dose was 40 Gy in 5
fractions, which was completed in October 2013. The
patient died in June 2014. The second patient with CP
score C10 had a tumor volume of 14.8 cm3 and mean
liver dose of 4.8 Gy. Prescription dose was 40 Gy in 5
fractions and radiation was completed in September 2016.
This patient died in March 2017. The patient who died of
an unknown cause had a CP score of B9 with multiple
medical comorbidities including atrial fibrillation,
Table 2 Tumor details and treatment parameters
Variable Median Range
Size (cm) 3.05 0.7-10
GTV volume (cm3) 24.65 5-273
EQD2 (Gy) 71.7 40-126
Interval from RT to LT (days) 287 9-2100
Prescribed dose (Gy) 50 30-63
Mean liver dose (Gy) 8.6 2.4-11
Abbreviations: EQD2 Z equivalent dose in 2 Gray fractions;
GTVZ gross tumor volume; LTZ liver transplant; RTZ radiation
therapy.
Table 3 Radiographic and pathologic outcomes
Outcome Number %
Radiographic (n Z 21)
cPR 5 24
cCR 16 76
Pathologic (n Z 26)
pPR 10 38
pCR 16 62
Abbreviations: cCR Z clinical complete response; cPR Z clinical
partial response; pCR Z pathologic complete response; pPR Z
pathologic partial response.
Table 1 Clinical and radiation therapy characteristics of
patients
Variable Number %
Sex (n Z 20)
Male 15 75
Female 5 25
Imaging within Milan (n Z 20)
Yes 17 85
No 3 15



















Prior treatments to lesion (n Z 26)




TACE and RFA 1 3.8
MWA 1 3.8
None 4 15
Abbreviations: DEB-TACE Z drug-eluting bead transarterial che-
moembolization; MWA Z microwave ablation; RFA Z radio-
frequency ablation; TACE Z transarterial chemoembolization;
TAE Z transarterial embolization.
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hepatitis C and alcoholic cirrhosis, and hypertension. This
patient had an admission for altered mental status and
experienced a fall just a few days before their death. Two
patients dropped out due to HCC progression beyond
Milan criteria. One developed diffuse carcinomatosis of
the liver with relative sparing of the region treated with
SBRT. The second patient achieved local control of the
tumor treated with SBRT but developed progression
elsewhere in the liver. The remaining 1 patient developed
a new head and neck malignancy, which led to ineligi-
bility for transplant but was not classified as a dropout.
There was no significant correlation between increasing
tumor size and pCR rate (odds ratio [OR], 0.95; 95%
confidence interval, 0.595-1.53) for the patients treated, as
well as no significant correlation between pCR rate and
EQD2 (OR, 1.03; 95% confidence interval, 0.984-1.07).
The median follow-up was 42.2 months for patients who
underwent LT. There was a 1-year overall survival (OS)
of 94.7%, 2-year OS of 84.2%, and 4-year OS of 71.7%
for patients who underwent transplant. The median sur-
vival was not reached.
None of the patients experienced radiation-related
operative or postoperative complications. One patient
with a CP score of B7 treated with SBRT for unifocal
HCC located in the left lobe of the liver measuring 2.9 cm
completed radiation in January 2016 and underwent LT 7
months later in August 2016. He was found to have a
diaphragmatic hernia that was considered to possibly be
radiation related. The patient’s liver lesion was left sided
with minimal to no dose at the location of the right-sided
hernia, as seen in Figure 1, and therefore deemed unre-
lated to radiation. Another patient with a 2.7 cm unifocal
HCC in segments 7 and 8 received SBRT in June 2016
and underwent LT in August 2017. This patient devel-
oped hematemesis 2 weeks postoperatively and was
found to have a gastric perforation in the anterolateral
aspect of the stomach close to the lesser curvature. The
maximum radiation dose delivered to this area was 2.21
Gy and thus, this is not likely to be attributed to radiation.
One patient developed an intra-abdominal hematoma after
LT but was found to have a supratherapeutic international
normalized ratio on coumadin and the location of the
hematoma was far from the radiation field.
The most commonly seen acute toxicity during SBRT
in this set of patients was grade 1 to 2 fatigue. Four pa-
tients, or 20%, developed progression of their CP score
after SBRT. There were no patients with progression
greater than 2 points. One patient with initial CP score A5
developed a transient increase by 1 point, which later
normalized. Another patient with a CP score of A5
developed progression by 1 point due to initiation of
coumadin. One patient with CP score C10 had progres-
sion by 1 point, which persisted, and the final patient with
initial CP score of A6 had a progression by 2 points,
which eventually partially recovered to 1, or B7.
Discussion
One of the first liver SBRT experiences that demon-
strated this was a feasible treatment modality for patients
with primary HCC and metastatic lesions showed an
excellent response with all tumors, exhibiting either
reduction in size or stability and limited toxicity
compared with conventional RT.5 Patients who are listed
for transplant face the risk of dropout due to tumor pro-
gression, and therefore, bridging therapies are key com-
ponents in their management. SBRT is an effective local
therapy due to its ability to deliver high doses with
improved conformality and is often recommended when
patients are not eligible for other local therapies. These
data demonstrate that SBRT as a bridging modality is a
feasible option, with 1 of the highest reported pCR rates
to date of 62% among our patients. Other institutions that
have treated with SBRT as a bridge to transplant have
reported pCR rates ranging from 14% to 100%.8-13 Fac-
ciuto et al8 reported a pCR rate for 17 patients treated with
SBRT of only 14%, which could be attributed to a lower
range of radiation doses of 24 to 36 Gy in 2 to 4 fractions.
O’Connor et al9 delivered a higher median SBRT dose of
51 Gy in 3 fractions to 10 patients with a pCR rate of
27%, though there was also a higher median tumor size of
3.4 cm relative to patients in our study. The University of
Pittsburgh experience, including 12 patients, reported a
pCR rate of 46%. In their study, the median dose deliv-
ered was 40 Gy in 5 fractions, although their patients also
had a lower median tumor size of 2.3 cm.10 The Uni-
versity of Alabama treated 12 patients with planned
combined modality therapy of TACE and SBRT, and of
Figure 1 Image of the stereotactic body radiation therapy plan
for the treatment of a unifocal hepatocellular carcinoma of the
left lobe of the liver with radiation completed in January 2016.
The teal line represents the 50% isodose line and the yellow line
represents the 100% isodose line, which encompasses the tumor.
The patient underwent orthotopic liver transplantation in August
2016 and was found to have a right diaphragmatic hernia.
Minimal dose was delivered to the right diaphragm as seen on
this representative axial slice.
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the 6 who went on to transplant, there was a 100% pCR
rate and patients were successfully down staged to within
Milan criteria.13 A summary of our outcomes with those
of all of the aforementioned studies is shown in Table 4.
Tumor control probability curves using the linear-
quadratic model, taking into account the radiosensitivity
of HCC, have suggested that increasing the EQD2 has
minimal additional effect on control for tumor diameters
>2 cm. Additionally, tumor control begins to plateau with
increasing the EQD2 above approximately 45 to 50 Gy.14
The median EQD2 in our study was 71.7 Gy with a range
of 40 to 126 Gy and median tumor size was 3.05 cm. So,
although our statistical analysis demonstrated no corre-
lation between tumor size and pCR rate or delivered
EQD2 and pCR rate, it is possible this may be due to the
fact that doses delivered to the tumor sizes in our patient
population were sufficiently high to achieve a complete
response on pathology. Additionally, only 15% of the
lesions treated at our institution had not received any prior
treatment with local therapy. Of the others, 50% were
treated as a part of a combined modality approach and
50% were treated for salvage. Among all of the afore-
mentioned studies with comparatively lower pCR rates, a
majority of the lesions had not received any prior local
treatments.
SBRT as a bridging modality provides comparable
pCR rates and dropout rates to that of other local thera-
pies, of which the most commonly reported are TACE
and RFA. In a study by Sapisochin et al,RFA, TACE, and
SBRT outcomes were compared with pCR rates of
49.2%, 24.3%, and 13.3%, respectively.6 Of note, these
patients were offered SBRT because they were ineligible
for other treatments due to poorer baseline liver function,
technical limitations, or progression after TACE/RFA.
RFA was delivered to patients with smaller and fewer
lesions. Dropout rates for the 3 modalities were not
significantly different, ranging from 16.7% for SBRT,
20.2% for TACE, and 16.8% for RFA.6 Mohamed et al15












Facciuto et al8 17, 22 24-36 Gy in 2-4 fx 2.01 cm 14% 30% NR 2 patients with post-SBRT
nausea, 1 patient with
acute liver decompensation
O’Connor et al9 10, 11 33-54 Gy in 3 fx 3.4 cm 27% NR 0% 40% with acute grade 1-2
toxicity, no grade 3 toxicity
Gresswell et al10 12, 17 30-50 Gy in 4-6 fx 2.3 cm 46% 80% 8% No grade 3 acute toxicity
Moore et al11 23, NR 30-54 Gx in 3-5 fx 2.5 cm 27.3 % NR 30% 1 patient (CP B8) developed
RILD
Uemura et al12 22, 25 40-50 Gy in 4-6 fx 3.2 cm 28% NR 9% No grade 3 toxicity
Jacob et al13 12, 18 27-45 Gy in 2-6 fx 4.2 cm 100% NR 42% No grade 3 toxicity
Garg et al
(current study)
20, 26 30-63 Gy in 3-6 fx 3.05 cm 62% 76% 22% No grade 3 toxicity
Abbreviations: cCR Z clinical complete response; CP Z Child-Pugh; HCC Z hepatocellular carcinoma; NR Z not reported; pCR Z pathologic
complete response; RILD Z radiation-induced liver disease; RT Z radiation therapy; SBRT Z stereotactic body radiation therapy.
Figure 2 Clinical complete response demonstrated on post-stereotactic body radiation therapy magnetic resonance imaging on
September 26, 2017, which was discordant with explant pathology, which revealed pathologic partial response (pPR). The blue circle on
the magnetic resonance imaging highlights the location of the tumor. Stereotactic body radiation therapy was completed October 9, 2016
(30 Gy in 5 fractions) and liver transplantation was performed October 30, 2017.
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also published a comparison of local therapies, with a
reported RFA pCR rate of 60%, a TACE pCR rate of
28.5%, and an SBRT pCR rate of 28.5%. Overall, re-
ported pCR rates for RFA have ranged from 21% to 75%,
with dropout rates ranging from 17% to 21%.6,15-21 For
TACE, reported pCR rates have ranged from 24%
to 44%, with dropout rates ranging from 20% to
25%.6,15,22-24 In our study, pCR was achieved in 62% of
tumors and dropout rate was 22%, comparing favorably
with outcomes of other local treatment modalities.
There was a higher clinical complete response rate of
76% for patients who had imaging performed before
transplant, suggesting that there is an overprediction of
response based on imaging. Figure 2 demonstrates an
example of discordance between radiographic and path-
ologic findings on liver explant. The mRECIST criteria
are used to evaluate imaging and was developed in 2008
by the Association for the Study of Liver Disease to
incorporate changes in enhancement when evaluating
response.25 SBRT causes radiographic changes sur-
rounding the treated lesion, including abnormal
enhancement on arterial and venous phases and T2
hyperintensity, which can make interpretation chal-
lenging.26,27 An analysis of our imaging response criteria
is likely warranted. Other factors including absence of
high intensity on T2-weighted and diffusion-weighted
images have been suggested to be better predictors of
response.27 Further investigation into an optimal method
of radiologic interpretation is necessary, as radiographic
response is crucial in determining next treatment steps.
In our study, radiation treatment was very well tolerated.
The most commonly seen toxicity was mild to moderate
fatigue. There was 20% progression of CP score after
treatment. However, of these 4 patients, 1 had normaliza-
tion of their CP score and another was attributed to begin-
ning coumadin after SBRT. It is necessary to highlight the
importance of patient selection when considering patients
for bridging therapy such as SBRT. A majority of publi-
cations have primarily included patients who are CP class
A. In patients with borderline liver function or CP class C,
the concern is that the risks of treatment-related toxicity,
such as worsening liver function and death due to liver
failure, outweigh the potential benefits. This must be taken
into account when selecting patients for SBRT. There were
no radiation-related operative or postoperative complica-
tions in our series. There were cases of diaphragmatic
hernia, gastric perforation, and intra-abdominal hematoma,
whichwere all found to be located distant from the radiation
treatment field such that these areas received negligible
radiation dose. This is consistent with the findings of the
National Cancer Database analysis by Hasan et al,28 which
identified 165 patients treated with RT before LT without
significant increase in perioperative mortality or hospital
length of stay.
This study has limitations, including the retrospective
nature of this review, which can lead to selection bias and
underreporting of toxicities. In addition, the sample size
was small, which decreases the likelihood of finding
significant associations on multivariate analysis.
However, the lack of correlation with pCR rate and tumor
size or EQD2 is consistent with findings in other studies
and would support not treating to higher doses. Further-
more, in this report we did not directly compare outcomes
with SBRT to that of other bridging modalities from our
own institution. Regardless, this study provides value, as
despite its small sample size it is one of the largest
retrospective reviews of this nature in publication. Addi-
tionally, this provides further insight into the lack of
radiation-related operative complications as well as
limited long-term toxicities due to excellent and thorough
follow-up of these patients.
Further investigation is warranted to address other
questions, such as the benefits of upfront combined mo-
dality therapy with various bridging modalities versus
using these treatments as salvage by deploying them
sequentially as needed. There are several ongoing pro-
spective trials that may provide information, including the
University of Pennsylvania trial of TACE versus TACE
combined with SBRT as a bridge to transplant. Other
trials that are underway include the Lahey Clinic trial of
TACE versus SBRT as a bridge to transplant and the
Canadian trial of observation versus SBRT in patients
ineligible for TACE or RFA, which will provide much
needed prospective data.
Conclusions
Our data demonstrate that SBRT is a feasible bridging
modality to be offered to patients, with pCR and dropout
rates comparable to those of other known alternatives.
There were no additional radiation-related operative or
postoperative complications. The treatment was very well
tolerated, with limited toxicity and good survival out-
comes. There was no dose dependence or size dependence
for pCR rate, which may indicate that for the tumor sizes
in this study, the radiation doses delivered were suffi-
ciently high.
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